Anti-inhibitor coagulant complex (Baxalta)

N/A

Report date: 2026/03/12 20:00:16

Base Information

Drug NameAnti-inhibitor coagulant complex (Baxalta)
Drug Alias NameFactor VIII Inhibitor Bypassing Activity抗凝血酶抑制剂复合物Human Prothrombin Complex (Takeda)FeibaProthromplex TOTAL +[14] 
ClassificationBiologics > Blood components
Mechanisms of ActionCoagulation factor VII modulatorsCoagulation factor X modulatorsCoagulation factor IX modulators +[4] 
TargetsCoagulation factor VIIProthrombinCoagulation factor IX +[4] 
Therapy Area/IndicationsHemorrhageHemophilia BHemophilia A +[7] 
Global Approved IndicationsHemophilia BHemophilia A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1979/12/21
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesBaxalta IncorporatedNorthwell Health, IncTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesOregon Health And Science UniversityTulane University School Of Medicine
Active IndicationsHemorrhageHemophilia BHemophilia A +[5] 
Inactive IndicationsBlood Coagulation Disorders, InheritedCardiovascular Diseases

Other Information

ATC CodeB02BD03
Related LinksDrugBankKEGG